Navigation Links
Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%

ALLEGAN, Mich., Aug. 30, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina® Ketoconazole Foam, 2%. Perrigo has commenced shipping of the product and was first to file, enabling 180 days of marketing exclusivity. This product is part of the Perrigo/Cobrek collaboration.

Extina® Ketoconazole Foam, 2% has annual retail sales of approximately $10 million dollars. This product is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This launch reflects our continuing investment in new products. It is an example of the excellent partnership we have with Cobrek for developing foam products which is a key product category for our Rx business. Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
2. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
3. Perrigo Closes Acquisition of Paddock Labs
4. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
5. Perrigo Provides Update on Acquisition of Paddock Labs
6. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
7. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
8. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
9. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
10. Perrigo Announces Settlement of Cutivate Lotion Litigation
11. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... has found that immunotherapy can be efficiently combined with ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied ... the need to integrate dose form selection in early phase drug development. The ... organization supporting and bringing together the UK’s emerging life sciences companies, corporate partners, ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of ... Empowerment ™ attracts volunteers together who want to combine talents and resources to ... stakeholders in the process. The non-profit launched its first major fundraiser on November ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
Breaking Medicine News(10 mins):